Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers

Table 1 Clinical and pathological information for 27 adenocarcinomas in the study

Tissueid	Age	Sex	Stage	Cell*	Diff^#	Grade⁺	Status	TTLF
Lu1031	57	Female	IA	AD	Well	II	0	8.59
Lu1050	58	Male	IB	AD	Well	II	0	7.54
Lu1068	57	Female	IB	AD	Mod	III	1	3.28
Lu106	63	Male	IB	AD	Well	II	0	11.96
Lu113	89	Female	IA	AD	Well	II	1	5.68
Lu1182	61	Female	IA	BAC	Well	II	0	8.24
Lu1321	68	Female	IB	AD	Well	II	0	6.75
Lu1377	64	Female	IA	AD	Well	II	0	0.36
Lu1405	54	Female	IB	AD	Mod	III	0	8.03
Lu1450	74	Female	IB	AD	Well	II	0	8.08
Lu1479	64	Female	IA	AD	Well	II	0	8.08
Lu1518	55	Female	IB	AD	Mod	III	0	8.01
Lu1606	88	Female	IA	AD	Well	II	0	6.75
Lu1659	71	Female	IA	AD	Well	II	1	4.09
Lu1682	74	Female	IA	AD	Well	II	1	3.60
Lu1790	73	Female	IB	AD	Well	II	0	6.20
Lu1821	32	Male	IB	AD	Mod	III	0	6.47
Lu1848	46	Female	IB	AD	Well	II	0	5.29
Lu1942	70	Male	IB	AD	Mod	III	1	1.38
Lu1943	82	Female	IB	AD	Well	II	1	5.99
Lu2029	58	Female	IB	AD	Well	II	0	6.46
Lu2040	79	Female	IB	AD	Mod	III	0	0.78
Lu2368	58	Female	IB	AD	Mod	III	1	2.98
Lu2499	74	Female	IB	BAC	Well	I	0	5.03
Lu2502	77	Female	IA	BAC	Well	II	0	5.13
Lu346	67	Female	IA	AD	Well	II	0	5.08
Lu587	72	Female	IB	BAC	Well	I	0	5.85

*Tumor cell subtype. AD-adenocarcinoma, BAC-bronchioalveolar carcinoma (adenocarcinoma in situ according to 2011I ASLC/ATS/ERS classification). ⁺Grade – Mayo 4 level grade of differentiation. ^#Diff – summarized tumor degree of differentiation from grade. I-II well, III- moderate, IV – Poorly/undifferentiated. TTLF – time to last follow up in years; status – 1 death, 0 alive.